Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

Time to progression of disease (POD) after first-line (1L) therapy is prognostic in mantle cell lymphoma (MCL), although studies have included a broad range of 1L, second-line (2L), and subsequent lines of therapy. The purpose of this study was to evaluate the factors predicting outcomes in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Villa, Diego, Jiang, Aixiang, Visco, Carlo, Crosbie, Nicola, McCulloch, Rory, Buege, Michael J., Kumar, Anita, Bond, David A., Paludo, Jonas, Maurer, Matthew J., Thanarajasingam, Gita, Lewis, Katharine L., Cheah, Chan Y., Baech, Joachim, El-Galaly, Tarec C., Kugathasan, Laveniya, Scott, David W., Gerrie, Alina S., Lewis, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425680/
https://www.ncbi.nlm.nih.gov/pubmed/37307169
http://dx.doi.org/10.1182/bloodadvances.2023009804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425680/
https://www.ncbi.nlm.nih.gov/pubmed/37307169
http://dx.doi.org/10.1182/bloodadvances.2023009804

Ejemplares similares